Local gene delivery of tumor necrosis factor alpha can impact primary tumor growth and metastases through a host-mediated response

Clinical and Experimental Metastasis

Volumn 24, Issue 7, 2007, Pages 521-531

  MacGill, Randall S ^a   Davis, Thomas A ^a,c   Macko, Jennifer ^a,c   Mauceri, Helena J ^b   Weichselbaum, Ralph R ^b   King, C Richter ^a  

^a GENVEC INC   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c Celldex Therapeutics Inc   (United Kingdom)

Author keywords

Adenovector; Clinical trial; Gene therapy; Melanoma; TNFerade; Tumor necrosis factor

Indexed keywords

ADENOVIRUS VECTOR; TNFERADE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG POTENCY; FEMALE; GENE TARGETING; HISTOCHEMISTRY; HYPOTHESIS; KNOCKOUT MOUSE; LOCAL THERAPY; LYMPH NODE METASTASIS; MELANOMA; METASTASIS INHIBITION; MOUSE; MOUSE STRAIN; NONHUMAN; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ADULT; ANIMALS; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; FOLLOW-UP STUDIES; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; NEOPLASM TRANSPLANTATION; NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34948821201     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10585-007-9089-3     Document Type: Article

References (65)

1. Mueller H (1998) Tumor necrosis factor as an antineoplastic agent: pitfalls and promises. Cell Mol Life Sci 54(12):1291-1298
2. Weichselbaum RR, Kufe DW, Hellman S et al (2002) Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy. Lancet Oncol 3(11):665-671
3. Senzer N, Mani S, Rosemurgy A et al (2004) TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol 22(4):592-601
4. McLoughlin JM, McCarty TM, Cunningham C et al (2005) TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up. Ann Surg Oncol 12(10):825-830
5. Balch CM, Buzaid AC, Soong SJ et al (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19(16):3635-3648
6. Balch CM, Soong SJ, Gershenwald JE et al (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19(16):3622-3634
7. Yamashita Y, Shimada M, Tanaka S et al (2002) Electroporation-mediated tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L gene therapy for hepatocellular carcinoma. Hum Gene Ther 13(2):275-286
8. Mastrangelo MJ, Maguire HC Jr, Eisenlohr LC et al (1999) Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 6(5):409-422
9. Rochlitz C, Jantscheff P, Bongartz G et al (1999) Gene therapy study of cytokine-transfected xenogeneic cells (Vero-interleukin-2) in patients with metastatic solid tumors. Cancer Gene Ther 6(3):271-281
10. Nasu Y, Bangma CH, Hull GW et al (1999) Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Ther 6(3):338-349
11. Triozzi PL, Strong TV, Bucy RP et al (2005) Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma. Hum Gene Ther 16(1):91-100
12. Harada N, Shimada M, Okano S et al (2004) IL-12 gene therapy is an effective therapeutic strategy for hepatocellular carcinoma in immunosuppressed mice. J Immunol 173(11):6635-6644
13. Lucas ML, Heller R (2003) IL-12 gene therapy using an electrically mediated nonviral approach reduces metastatic growth of melanoma. DNA Cell Biol 22(12):755-763
14. Karavodin LM, Robbins J, Chong K et al (1998) Generation of a systemic antitumor response with regional intratumoral injections of interferon gamma retroviral vector. Hum Gene Ther 9(15):2231-2241
15. Alizadeh H, Howard K, Mellon J et al (2003) Reduction of liver metastasis of intraocular melanoma by interferon-beta gene transfer. Invest Ophthalmol Vis Sci 44(7):3042-3051
16. Izawa JI, Sweeney P, Perrotte P et al (2002) Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res 8(4):1258-1270
17. Cao G, Su J, Lu W et al (2001) Adenovirus-mediated interferon-beta gene therapy suppresses growth and metastasis of human prostate cancer in nude mice. Cancer Gene Ther 8(7):497-505
18. McDermott MF (2001) TNF and TNFR biology in health and disease. Cell Mol Biol (Noisy-le-grand) 47(4):619-635
19. Palladino MA, Bahjat FR, Theodorakis EA et al (2003) Anti-TNF-alpha therapies:the next generation. Nat Rev Drug Discov 2(9):736-746
20. Kim EY, Teh HS (2001) TNF type 2 receptor (p75) lowers the threshold of T cell activation. J Immunol 167(12):6812-6820
21. Alexander-Miller MA, Derby MA, Sarin A et al (1998) Supraoptimal peptide-major histocompatibility complex causes a decrease in bc1-2 levels and allows tumor necrosis factor alpha receptor II-mediated apoptosis of cytotoxic T lymphocytes. J Exp Med 188(8):1391-1399
22. Zheng L, Fisher G, Miller RE et al (1995) Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377(6547):348-351
23. Brunner C, Seiderer J, Schlamp A et al (2000) Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J Immunol 165(11):6278-6286
24. Kianmanesh A, Hackett NR, Lee JM et al (2001) Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor alpha together with naive dendritic cells elicits significant suppression of tumor growth without toxicity. Hum Gene Ther 12(17):2035-2049
25. Fujiwara H, Yamauchi N, Sato Y et al (2000) Synergistic suppressive effect of double transfection of tumor necrosis factor-alpha and interleukin 12 genes on tumorigenicity of Meth-A cells. Jpn J Cancer Res 91(12):1296-1302
26. Baxevanis CN, Voutsas IF, Tsitsilonis OE et al (2000) Compromised anti-tumor responses in tumor necrosis factor-alpha knockout mice. Eur J Immunol 30(7):1957-1966
27. Lee RK, Spielman J, Zhao DY et al (1996) Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells. J Immunol 157(5):1919-1925
28. Fukumura D, Salehi HA, Witwer B et al (1995) Tumor necrosis factor alpha-induced leukocyte adhesion in normal and tumor vessels: effect of tumor type, transplantation site, and host strain. Cancer Res 55(21):4824-4829
29. Madge LA, Pober JS (2001) TNF signaling in vascular endothelial cells. Exp Mol Pathol 70(3):317-325
30. Peter I, Mezzacasa A, LeDonne P et al (2001) Comparative analysis of immunocritical melanoma markers in the mouse melanoma cell lines B16, K1735 and S91-M3. Melanoma Res 11(1):21-30
31. Douin-Echinard V, Bornes S, Rochaix P et al (2000) The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status. Cancer Gene Ther 7(12):1543-1556
32. van Elsas A, Hurwitz AA, Allison JP (1999) Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190(3):355-366
33. Geertsen R, Hofbauer G, Kamarashev J et al (1999) Immune escape mechanisms in malignant melanoma. Int J Mol Med 3(1):49-57
34. Geertsen RC, Hofbauer GF, Yue FY et al (1998) Higher frequency of selective losses of HLA-A and -B allospecificities in metastasis than in primary melanoma lesions. J Invest Dermatol 111(3):497-502
35. Alvarez E (2002) B16 murine melanoma. In: Teicher B (ed) Tumor models in cancer research. Human Press, Totowa, NJ, pp 73-89
36. Datta R, Taneja N, Sukhatme VP et al (1993) Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation. Proc Natl Acad Sci USA 90(6):2419-2422
37. Datta R, Rubin E, Sukhatme V et al (1992) Ionizing radiation activates transcription of the EGR1 gene via CArG elements. Proc Natl Acad Sci USA 89(21):10149-10153
38. Hallahan DE, Sukhatme VP, Sherman ML et al (1991) Protein kinase C mediates x-ray inducibility of nuclear signal transducers EGR1 and JUN. Proc Natl Acad Sci USA 88(6):2156-2160
39. Hallahan DE, Mauceri HJ, Seung LP et al (1995) Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1(8):786-791
40. Lopez CA, Kimchi ET, Mauceri HJ et al (2004) Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity. Mol Cancer Ther 3(9):1167-1175
41. Park JO, Lopez CA, Gupta VK et al (2002) Transcriptional control of viral gene therapy by cisplatin. J Clin Invest 110(3):403-410
42. McVey D, Zuber M, Ettyreddy D et al (2002) Rapid construction of adenoviral vectors by lambda phage genetics. J Virol 76(8):3670-3677
43. Brough DE, Lizonova A, Hsu C et al (1996) A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol 70(9):6497-6501
44. Kovesdi I, Ransom SC (2003) United States Patent #6,514,943: method and composition for preserving viruses. GenVec, Inc., USA
45. Carlsson G, Gullberg B, Hafstrom L (1983) Estimation of liver tumor volume using different formulas - an experimental study in rats. J Cancer Res Clin Oncol 105(1):20-23
46. Mundt AJ, Vijayakumar S, Nemunaitis J et al (2004) A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res 10(17):5747-5753
47. Rasmussen H, Rasmussen C, Lempicki M et al (2002) TNFerade biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene. Cancer Gene Ther 9(11):951-957
48. Donnelly EF, Geng L, Wojcicki WE et al (2001) Quantified power Doppler US of tumor blood flow correlates with microscopic quantification of tumor blood vessels. Radiology 219(1):166-170
49. Butler TP, Gullino PM (1975) Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res 35(3):512-516
50. Cook MJ (1965) The anatomy of the laboratory mouse. Academic Press, London
51. Lindena J, Trautschold I (1983) Ductus thoracicus lymph in mice. 1. A technique for cervical approach. Lymphology 16(4):243-246
52. Tilney NL (1971) Patterns of lymphatic drainage in the adult laboratory rat. J Anat 109(Pt 3):369-383
53. Lewis M, Tartaglia LA, Lee A et al (1991) Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci USA 88(7):2830-2834
54. Mauceri HJ, Hanna NN, Wayne JD et al (1996) Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res 56(19):4311-4314
55. Fidler IJ (1995) Melanoma metastasis. Cancer Control 2(5):398-404
56. Leiter U, Meier F, Schittek B et al (2004) The natural course of cutaneous melanoma. J Surg Oncol 86(4):172-178
57. Nathanson SD (2003) Insights into the mechanisms of lymph node metastasis. Cancer 98(2):413-423
58. Steeg PS (2006) Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12(8):895-904
59. Wiley HE, Gonzalez EB, Maki W et al (2001) Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst 93(21):1638-1643
60. Essner R (2006) Experimental frontiers for clinical applications: novel approaches to understanding mechanisms of lymph node metastases in melanoma. Cancer Metastasis Rev 25(2):257-267
61. Kaplan RN, Riba RD, Zacharoulis S et al (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438(7069):820-827
62. Steeg PS (2005) Cancer biology: emissaries set up new sites. Nature 438(7069):750-751
63. Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411(6835):380-384
64. Ribas A (2006) Update on immunotherapy for melanoma. J Natl Compr Canc Netw 4(7):687-694
65. Atkins MB (2006) Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 12(7 Pt 2):2353s-2358s